Iteos Therapeutics Inc (ITOS)

Dec 17, 2024, 7:01 PM EST - 4 weeks ago

iTeos Therapeutics: A Perhaps Unjustified Decline To End 2024

Dec 12, 2024, 8:55 AM EST - 5 weeks ago

iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress

Nov 26, 2024, 7:00 AM EST - 7 weeks ago

iTeos to Participate in Upcoming Investor Conferences

Nov 12, 2024, 7:00 AM EST - 2 months ago

iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates

Sep 16, 2024, 8:44 AM EDT - 4 months ago

iTeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session

UPST

Sep 15, 2024, 3:37 AM EDT - 4 months ago

iTeos Therapeutics: ESMO Data Showing Signs Of A Real Win For TIGIT

Sep 14, 2024, 2:30 AM EDT - 4 months ago

iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients

Aug 20, 2024, 8:30 AM EDT - 5 months ago

iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024

Aug 5, 2024, 7:00 AM EDT - 5 months ago

iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer

Jul 8, 2024, 9:00 PM EDT - 6 months ago

iTeos Therapeutics: Rippling Waves Of TIGIT Pessimism

Jul 8, 2024, 7:00 AM EDT - 6 months ago

iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK

Jun 17, 2024, 9:00 AM EDT - 7 months ago

iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer

May 10, 2024, 9:45 AM EDT - 9 months ago

iTeos Therapeutics to raise $120 million via registered direct offering

May 10, 2024, 8:26 AM EDT - 9 months ago

iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates

May 10, 2024, 8:24 AM EDT - 9 months ago

iTeos Therapeutics Announces $120 Million Registered Direct Offering

Apr 7, 2024, 4:30 PM EDT - 10 months ago

iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024

Mar 6, 2024, 7:01 AM EST - 11 months ago

iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors

Mar 6, 2024, 7:00 AM EST - 11 months ago

iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Mar 5, 2024, 4:30 PM EST - 11 months ago

iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024

Jan 10, 2024, 8:01 AM EST - 1 year ago

iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch

AGEN BMY CGEN GSK MRK NVS PFE

Nov 21, 2023, 7:00 AM EST - 1 year ago

iTeos to Present at the Piper Sandler 35th Annual Healthcare Conference

Nov 7, 2023, 7:00 AM EST - 1 year ago

iTeos Reports Third Quarter 2023 Financial Results and Provides Business Updates

Nov 4, 2023, 9:00 AM EDT - 1 year ago

iTeos Therapeutics: Trying Hard Where The Big Guys Might Still Fail

Aug 25, 2023, 3:55 PM EDT - 1 year ago

iTeos Therapeutics And The TIGIT Ticket To Cancer's Downfall

Aug 23, 2023, 8:45 AM EDT - 1 year ago

Gilead, Arcus, iTeos, other biopharmas get boost from accidental disclosure of Roche lung cancer trial data

GILD RCUS

Aug 8, 2023, 7:00 AM EDT - 1 year ago

iTeos Reports Second Quarter 2023 Financial Results and Provides Business Updates

Jun 4, 2023, 10:04 AM EDT - 1 year ago

iTeos Therapeutics: Trading Under Cash Value

May 10, 2023, 7:01 AM EDT - 1 year ago

iTeos Reports First Quarter 2023 Financial Results and Provides Business Updates

Mar 15, 2023, 7:00 AM EDT - 2 years ago

iTeos Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

Mar 2, 2023, 2:41 PM EST - 2 years ago

iTeos Therapeutics: Able To Pull In Big Pharma Deals, Needs Follow-Through

Feb 28, 2023, 7:00 AM EST - 2 years ago

iTeos to Present at Cowen 43rd Annual Health Care Conference

Feb 7, 2023, 7:00 AM EST - 2 years ago

iTeos to Present at SVB Securities Global Biopharma Conference

Jan 9, 2023, 7:00 AM EST - 2 years ago

iTeos Provides Business Updates and Clinical Development Plans for 2023

Jan 3, 2023, 7:00 AM EST - 2 years ago

iTeos to Present at the 41st Annual J.P. Morgan Healthcare Conference

Nov 22, 2022, 7:00 AM EST - 2 years ago

iTeos to Present at the Piper Sandler 34th Annual Healthcare Conference

Nov 10, 2022, 4:01 PM EST - 2 years ago

iTeos Reports Third Quarter 2022 Financial Results and Provides Business Updates

Aug 10, 2022, 4:01 PM EDT - 2 years ago

iTeos Reports Second Quarter 2022 Financial Results and Provides Business Update

Aug 2, 2022, 7:00 AM EDT - 2 years ago

iTeos to Present at the 2022 Wedbush PacGrow Healthcare Conference

Jun 13, 2022, 4:39 AM EDT - 2 years ago

Domain Therapeutics Appoints Dr Xavier Leroy as Chief Scientific Officer

May 12, 2022, 4:01 PM EDT - 2 years ago

iTeos Reports First Quarter 2022 Financial Results and Provides Business Update

Apr 12, 2022, 2:00 AM EDT - 3 years ago

Innoskel Appoints Dr Michel Detheux as Chairman

Apr 8, 2022, 1:00 PM EDT - 3 years ago

iTeos Presents New Data for Anti-TIGIT Antibody, EOS-448/GSK4428859A, at the AACR Annual Meeting 2022

Mar 23, 2022, 4:01 PM EDT - 3 years ago

iTeos Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Mar 1, 2022, 7:00 AM EST - 3 years ago

iTeos to Present at the Cowen 42nd Annual Health Care Conference

Feb 10, 2022, 7:00 AM EST - 3 years ago

iTeos to Participate in Upcoming Investor Conferences in February

Jan 10, 2022, 7:00 AM EST - 3 years ago

iTeos Provides Clinical Development Plans and Promotes Yvonne McGrath, Ph.D. to Chief Scientific Officer

Jan 3, 2022, 4:01 PM EST - 3 years ago

iTeos to Present at the 40th Annual J.P. Morgan Healthcare Conference

Dec 31, 2021, 5:44 PM EST - 3 years ago

iTeos Therapeutics Set to Join S&P SmallCap 600

CNC

Dec 9, 2021, 4:01 PM EST - 3 years ago

iTeos Announces New Data for its Anti-TIGIT Antibody, EOS-448, at the American Society of Hematology Annual Meeting and TIGIT Therapies Digital Summit 2021

Dec 7, 2021, 10:10 AM EST - 3 years ago

MPM Capital Announces the Addition of Detlev Biniszkiewicz, Ph.D. to its Investment Committee